Research Article

Puerarin Improves Diabetic Aorta Injury by Inhibiting NADPH Oxidase-Derived Oxidative Stress in STZ-Induced Diabetic Rats

Wenping Li,1,2 Wenwen Zhao,3 Qin Wu,1 Yuanfu Lu,1 Jingshan Shi,1 and Xiuping Chen3

1Key Lab for Pharmacology of Ministry of Education, Department of Pharmacology, Zunyi Medical College, Zunyi 563003, China
2Chengdu Chronic Diseases Hospital, Chengdu 610083, China
3State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau

Correspondence should be addressed to Jingshan Shi; shijs@zmc.edu.cn and Xiuping Chen; xpchen@umac.mo

Received 8 September 2015; Revised 30 October 2015; Accepted 3 November 2015

Academic Editor: Hiroshi Okamoto

Copyright © 2016 Wenping Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Puerarin is a natural flavonoid isolated from the TCM lobed kudzuvine root. This study investigated the effect and mechanisms of puerarin on diabetic aorta in rats.

Methods. Streptozotocin- (STZ-) induced diabetic rats were administered with puerarin for 3 weeks. Levels of serum insulin (INS), PGE2, endothelin (ET), glycated hemoglobin (GHb), H2O2, and nitric oxide (NO) in rats were measured by ELISA and colorimetric assay kits. The aortas were stained with H&E. Moreover, the mRNA expression of ICAM-1, LOX-1, NADPH oxidase 2 (NOX2), and NOX4 and the protein expression of ICAM-1, LOX-1, NF-κB p65, E-selectin, NOX2, and NOX4 in aorta tissues were measured by real-time PCR and Western blot, respectively. The localization of ICAM-1, NF-κB p65, NOX2, and NOX4 in the aorta tissues was also determined through immunohistochemistry.

Results. Puerarin treatment exerted no effect on fasting blood glucose levels but significantly reduced the serum levels of INS, GHb, PGE2, ET, H2O2, and NO. In addition, puerarin improved the pathological alterations and inhibited the expression of ICAM-1, LOX-1, NOX2, and NOX4 at both mRNA and protein levels. Puerarin also significantly reduced the number of cells showing positive staining for ICAM-1, NOX2, NOX4, and NF-κB p65.

Conclusion. Puerarin demonstrated protective effect on the STZ-induced diabetic rat aorta. The protective mechanisms may include regulation of NF-κB and inhibition of NOX2 and NOX4 followed by inhibition of cell adhesion molecule expression.

1. Introduction

Diabetes, a chronic disease characterized by hyperglycemia, has become a major health crisis worldwide. The global prevalence of diabetes in 382 million people in 2013 is estimated to rise to 592 million by 2035 [1]. Diabetes leads to an array of chronic microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (atherosclerosis, ischemic heart disease, stroke, and peripheral vascular disease) complications. These chronic complications are the major causes of the reduced quality of life among diabetics, increased burden to the health care system, and increased diabetes-related mortality [2]. Although the microvascular complications are directly related to the severity and duration of hyperglycemia, the macrovascular complications are the primary causes of mortality, with myocardial infarction and stroke accounting for 80% of all deaths among T2DM patients [3]. Therefore, inhibiting and alleviating the macrovascular complications have become a major challenge in diabetes treatment.

The vascular functions are tightly regulated by a series of vasoactive agents such as nitric oxide (NO), PGE2, and endothelin (ET) [4]. Furthermore, the adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) play important roles in endothelial dysfunction and vascular injury [5]. In addition, the NADPH oxidase (NOX family), one of the main sources of reactive oxygen species (ROS) in vascular, and NF-κB, the key transcription factor in regulating adhesion molecular expression, play important roles in diabetic vascular complications [6,7].

Puerarin is a natural, flavonoid-rich component of the Chinese herb lobed kudzuvine root. Previous findings showed that puerarin contains multiple bioactive compounds.
and has been widely used to treat cardiovascular and cerebrovascular diseases, osteonecrosis, Parkinson’s disease, Alzheimer’s disease, endometriosis, osteoporosis, liver injury, inflammation, and cancer [8, 9]. Studies also showed that puerarin improves diabetic complications by reducing blood glucose [10] and enhancing glucose uptake [11], thereby preventing retinopathy [12], improving insulin resistance (IR) [13], protecting the pancreatic β cells [14], improving cardiac function [15], and inhibiting oxidative stress [16], among others. However, its effect on diabetic macrovascular complications remains unclear. In the current research, the effect of puerarin on macrovascular complications was investigated in streptozotocin- (STZ-) induced diabetic rats.

2. Methods

2.1. Reagents. Puerarin injection was purchased from Hunan WZT Pharmaceutical Co., Ltd. (China). The STZ was obtained from Sigma (USA). The primers for ICAM-1, LOX-1, NADPH oxidase 2 (NOX2), NOX4, and β-actin were purchased from Generay, Inc. (Shanghai, China). The primary antibodies for ICAM-1, LOX-1, and NF-κB p65 were purchased from Proteintech Group, Inc. (Wuhan, China), Abcam (USA), and Boster (Wuhan, China), respectively, whereas those for NOX2, NOX4, and E-selectin were purchased from Santa Cruz Biotechnology.

2.2. Animals. Male Sprague Dawley rats (250–280 g) were purchased from the Experimental Animal Center of Daping Hospital. This study was approved by the Animal Ethics Committee of Zunyi Medical College. All rats were maintained on a 12 h alternating light/dark cycle at 22 ± 2 °C and 55%–60% humidity. Diabetes was induced by intraperitoneal (i.p.) injection of freshly prepared STZ in citrate buffer (dissolved in 0.1 mmol/L citrate buffer, pH 4.2–4.5) at a dosage of 60 mg/kg/day for 3 consecutive days. Eight non-diabetic control rats received an equal volume of citric buffer only. Rats with blood glucose levels of ≥16.7 mmol/L after 72 h administration of STZ were considered diabetic. These diabetic rats (24 rats) were randomly divided into 3 groups (8 each) and were administered with or without puerarin (18 and 45 mg/kg/day i.p.) for 3 weeks. Body weight and blood glucose levels were measured twice a week.

2.3. Determination of Fasting Blood Glucose (FBG). FBG was determined twice a week by using ONETOUCH Ultra Glucometer (Johnson & Johnson, USA) in accordance with the manufacturer’s instructions.

2.4. Determination of Serum Insulin (INS), Glycated Hemoglobin (GHB), PGE2, ET, H2O2, and NO Levels. Serum levels of INS, GHB, PGE2, ET, H2O2, and NO were determined using commercial ELISA kits (R&D, USA) in accordance with the manufacturer’s instructions.

2.5. H&E Staining. Aorta specimens were fixed in 4% neutral formaldehyde solution. After dehydration with graded alcohol solutions and xylene, the specimens were embedded in paraffin. The specimens were then cut into 5 μm thick cross sections and stained with H&E by conventional method.

2.6. RT-PCR. Total RNA was extracted from the aorta specimens with Trizol (Invitrogen) for cDNA synthesis by using a reverse transcription reaction kit (TaKaRa). Table 1 shows the primers for ICAM-1, LOX-1, NOX2, NOX4, and β-actin.

2.7. Western Blot. Total proteins were extracted from the aorta, and the protein contents were determined using a BCA Protein Assay Kit (Generay). Proteins (50 μg) were subjected to 8%–10% SDS-PAGE and then transferred onto PVDF membranes. After blocking with 5% nonfat milk in TBST at room temperature for 1 h, the membranes were washed thrice with TBST and then incubated overnight with specific primary antibodies (1:500–1:1000) at 4 °C. After washing with 5% nonfat milk/TBST, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 h. Protein-antibody complexes were detected by ECL Advanced Western Blot Detection Kit.

2.8. Immunohistochemistry. After the consecutive steps of deparaffinization, deactivation of endogenous peroxidase with 3% H2O2, and antigen blocking with 5% BSA-PBS, the sections were incubated with ICAM-1, NF-κB, NOX2, and NOX4 antibodies (1:50 dilution) at 37 °C for 2 h. After rinsing thrice with PBS, the sections were incubated with secondary antibody (Gene Tech, Shanghai, China) for 30 min at 37 °C and then stained using DAB chromogen kit (Beijing Zhongshans Golden Bridge Biotechnology Co., Ltd.).

2.9. Statistical Analysis. Data were expressed as means ± SD of at least three separate experiments. Statistical analysis was performed using SPSS 16.0, and differences between groups were analyzed by one-way ANOVA. A value of p < 0.05 was considered statistically significant.

3. Results

3.1. Effect of Puerarin on Body Weight and FBG. The average body weight of the control group increased significantly, whereas that of the model group decreased considerably. Puerarin treatment exerted no effect on body weight (Figure 1(a)). Moreover, the mean FBG of the control group was 5.1 mmol/L, which increased to 20.8 mmol/L after STZ injection approximately fourfold. Compared with the model group, the FBG levels of the high-dosage treatment group decreased, but this disparity was not statistically significant (Figure 1(b)).

3.2. Effect of Puerarin on Serum INS and GHB. Compared with the control group, the serum levels of INS and GHB in the diabetic rats increased significantly. Low-dose puerarin exerted no effect on either INS or GHB, whereas high-dosage puerarin significantly reduced both INS and GHB levels (Figures 1(c) and 1(d)).
### Table 1: Primers for RT-PCR.

| Gene    | Forward primer (5'-3') | Reverse primer (5'-3') |
|---------|------------------------|------------------------|
| NOX4    | CAGTCAAACAGATGGGATACAGA| ATAGAAGCTGGTCCACAGCAGA |
| ICAM-1  | GCTCAGGTATCCATCCATCCC | AGTTCTTCTTCTCCAGTTAGTCT |
| LOX-1   | TAACTGGGAAAAAAGTCGGGAGA| AATGGGAAAGTTTCTGTAAGACGAA |
| NOX2    | TGAATCTCAGGCCAATCTTT  | ATGGTCTGAACGTCTTACGCC |
| β-actin | CTGAACCCTAAGCCACCG    | GACCGAGGCATAACAGGACAA  |

**Figure 1:** Effect of puerarin on body weight (a), FBG (b), serum INS (c), and GHb in STZ-induced diabetic rats. **P < 0.01** versus Cont; **P < 0.01** versus Mod.Cont, control group; Mod, diabetic model group; Pue L, low dosage of puerarin; Pue H, high dosage of puerarin.

#### 3.3. Effects of Puerarin on Serum PGE2, ET, H2O2, and NO.

Compared with the control group, the serum levels of PGE2, ET, H2O2, and NO in diabetic rats significantly increased. These parameters were not affected by low-dose puerarin but significantly reduced by high-dose puerarin (Figure 2).

#### 3.4. Effect of Puerarin on Aorta Alterations.

H&E staining showed that the structure of each layer of the aorta was normal, and the smooth muscle cells were neatly arranged in rows. No damage or injury was observed in the control group, whereas the aortic wall was thickened and the adventitial fibrosis increased in the diabetic group. Furthermore, ruptured smooth muscles and increased nucleus were observed. These alterations were improved by both dosages of puerarin treatment, especially the high-dosage treatment (Figure 3).

#### 3.5. Effect of Puerarin on mRNA Expression of ICAM-1, LOX-1, NOX2, and NOX4.

Compared with the control group, the mRNA expression of ICAM-1, LOX-1, NOX2, and NOX4 increased significantly in diabetic rats. The mRNA expression levels of these genes were inhibited by puerarin in a dose-dependent manner (Figure 4).
Figure 2: Effect of puerarin on serum PGE2 (a), ET (b), H$_2$O$_2$ (c), and NO (d) in STZ-induced diabetic rats. $## P < 0.01$ versus Cont; $** P < 0.01$ versus Mod. Cont, control group; Mod, diabetic model group; Pue L, low dosage of puerarin; Pue H, high dosage of puerarin.

3.6. Effect of Puerarin on Protein Expression of ICAM-1, LOX-1, NOX2, NOX4, E-Selectin, and NF-κB p65. Compared with the control group, the protein expression levels of ICAM-1, LOX-1, and E-selectin (Figure 5), as well as those of NOX2, NOX4, and NF-κB p65 (Figure 6), increased significantly in diabetic rats and were inhibited by puerarin.

3.7. Effect of Puerarin on Localization of ICAM-1, NF-κB p65, NOX2, and NOX4. ICAM-1, NOX2, NOX4, and NF-κB p65 were lowly expressed in the endothelial and smooth muscle cells of the control group. By contrast, their expression increased significantly, especially in the smooth muscle cells of the aorta of diabetic rats, as indicated by the conspicuous brown granules. Puerarin treatment significantly reduced the amount of brown granules, suggesting the reduced expression of these proteins (Figure 7). Furthermore, high dosage of puerarin can almost completely inhibit the expression of ICAM-1 and NOX2.

4. Discussion
Diabetes, regardless of its clinical categories, is a metabolic disease characterized by high blood glucose level over a prolonged period. The diabetic vascular complications, the main cause of diabetic death, are closely connected with the sustained increase of glucose. In this study, we established a diabetic model with dramatic increase of glucose level, increase of serum INS, and decrease of body weight. Though these characteristics are not identical to classical type 1 or type 2 diabetic rat models, the increased glucose level was useful for the exploration of vascular protective agents.

Puerarin has been approved by the SFDA of China as an adjuvant treatment of coronary heart disease, myocardial infarction, and cerebrovascular disease. The present study investigated the effect of puerarin on the aorta of diabetic rats. STZ injection significantly induced hyperglycemia, increased INS, and reduced body weight, suggesting the development of diabetes. Puerarin exerted no effect on FBG of the STZ-induced diabetic rats, and this finding is consistent with previous report [17]. However, She et al. [16] showed that puerarin treatment reduced blood glucose levels and increased body weight. This disparity may be ascribed to the difference in dosage. Our dosage is less than half of that used by She et al. [16]. Moreover, blood GHb level plays a pivotal role in monitoring the long-term glycemic status of diabetes mellitus patients [18]. In the current study, although puerarin exerted no effect on FBG, puerarin reduced GHb, and this finding is consistent with previous observation on puerarin-treated diabetic patients [19]. Previous research also showed
Figure 3: Effect of puerarin on morphological alterations in STZ-induced diabetic rats. H&E staining, 200x. Pue L, low dosage of puerarin; Pue H, high dosage of puerarin.

Figure 4: Effect of puerarin on mRNA expression of ICAM-1 (a), LOX-1 (b), NOX2 (c), and NOX4 (d) in the aorta of STZ-induced diabetic rats. **p < 0.01 versus Cont; *p < 0.05 and ***p < 0.01 versus Mod. Cont, control group; Mod, diabetic model group; Pue L, low dosage of puerarin; Pue H, high dosage of puerarin.
that puerarin reversed the reduced INS in STZ-induced diabetic mice [20]. By contrast, we found that puerarin reversed the increased INS in STZ-induced diabetic rats. This effect of puerarin may be associated with its influence on IR [13]. The contraction and relaxation of vessels are strictly and precisely controlled by vasoactive substances, such as angiotensin II, ET, PGEs, and NO. Consistent with previous reports [21, 22], serum NO and H$_2$O$_2$ concentrations were significantly increased in diabetic rats. Although physiological levels of NO and H$_2$O$_2$ positively regulate the vascular function and homeostasis, nitrosative and oxidative stresses caused by excessive generation of them result in alterations of vascular reactivity and lead to vascular toxicity [23]. Increased PGE2 and ET secretions in diabetic vascular bed [24] and placenta [25] were also observed. These changes reflected diabetic vascular dysfunction, which was partly reversed by puerarin, suggesting that puerarin affects diabetic vascular nitrosative and oxidative stresses, and restored vascular tension. Furthermore, pathological alterations were detected in diabetic aorta. The thickened media were mainly caused by the proliferation of vascular smooth muscles, possibly resulting from increased amount of glucose [26]. These observations are consistent with the recent findings in which puerarin attenuates calcification of vascular smooth muscle cells (VSMCs) [27] and attenuates high-glucose- and diabetes-induced VSMC proliferation [28].

The vascular adhesion molecules ICAM-1, LOX-1, and E-selectin serve as biomarkers of vascular inflammation. Enhanced expression of these molecules was observed in high-glucose-treated endothelial cells [29, 30]. In the present study, both the expression of ICAM-1 and LOX-1 at mRNA and protein levels and the protein expression of E-selectin increased in diabetic aorta. Moreover, immunohistochemistry results showed that increased ICAM-1 was observed not only in endothelial cells but also in VSMCs. Puerarin inhibited the expression of these adhesion molecules, suggesting its inhibitory effect on vascular inflammation.

Oxidative stress plays a key role in diabetic complications in the kidney, heart, eye, or vasculature [31]. NOX is a major source of reactive oxygen species (ROS) and is a critical mediator of redox signaling in diabetes [32]. The NOX family comprises seven members, including NOX1–5, DUOX1, and DUOX2. NOX2 and NOX4 are widely expressed in vascular endothelial cells and VSMCs [32, 33]. We found herein a low expression of both NOX2 and NOX4 at mRNA and protein levels in the aorta. Immunohistochemistry results...
also showed that both endothelial cells and VSMCs expressed NOX2 and NOX4. In addition, their expression was significantly increased in STZ-induced diabetic rats, especially in their VSMCs. These results suggested that NOX was activated in diabetic aorta. Furthermore, superoxide anion and H\textsubscript{2}O\textsubscript{2} are the main products of NOX2 and NOX4, respectively, and the increased serum H\textsubscript{2}O\textsubscript{2} concentration is possibly caused by NOX4 activation. Previous studies showed that puerarin inhibits high-glucose-induced VSMC proliferation by interfering with PKC\textgamma/Rac1-dependent ROS [28]; moreover, puerarin inhibits retinal pericyte apoptosis induced by the end products of advanced glycation in vitro and in vivo by inhibiting NOX-related oxidative stress [34]. The inhibitory effect of puerarin on NOX2 and NOX4 expression in diabetic aorta suggested that the beneficial effect of puerarin is attributed to its inhibitory effect on NOX.

ROS is a key upstream activator of the NF-\kappaB pathway [35], which consequently regulates the expression of LOX-1, ICAM-1, and E-selectin [36–39]. The NF-\kappaB pathway was activated as evidenced by the increased protein expression of NF-\kappaB p65 in the diabetic aorta. Furthermore, the expression of NF-\kappaB p65 was colocalized with those of NOX2, NOX4, and ICAM-1, suggesting the potential role of NF-\kappaB. The inhibitory effect of puerarin on NF-\kappaB is possibly caused by the inhibitory effect of puerarin on NOX2 and NOX4, as well as its antioxidant activities [9].

In summary, this study showed that puerarin protected the diabetic aorta by inhibiting oxidative stress and adhesion molecule expression. This finding proves that puerarin can improve the macrovascular complications of diabetes.

**Conflict of Interests**

The authors declare no conflict of interests related to the present work.

**Acknowledgments**

This study was supported by the Science and Technology Development Fund, Macau (FDCT) (021/2012/A1), and the National Natural Science Foundation of China (no. 81160048).
Figure 7: Effect of puerarin on localization of ICAM-1 (a), NOX2 (b), NOX4 (c), and NF-κB p65 (d) proteins in the aorta as revealed by immunohistochemistry. Arrows, intensive expression.

References

[1] N. G. Forouhi and N. J. Wareham, “Epidemiology of diabetes,” Medicine, vol. 42, no. 12, pp. 698–702, 2014.

[2] Z. Liu, C. Fu, W. Wang, and B. Xu, “Prevalence of chronic complications of type 2 diabetes mellitus in outpatients—a cross-sectional hospital based survey in urban China,” Health and Quality of Life Outcomes, vol. 8, article 62, 2010.

[3] E. Ferrannini and R. A. DeFronzo, “Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes,” European Heart Journal, vol. 36, no. 34, pp. 2288–2296, 2015.

[4] J. Xu and M.-H. Zou, “Molecular insights and therapeutic targets for diabetic endothelial dysfunction,” Circulation, vol. 120, no. 13, pp. 1266–1286, 2009.

[5] T. Kita, N. Kume, M. Minami et al., “Role of oxidized LDL in atherosclerosis,” Annals of the New York Academy of Sciences, vol. 947, pp. 199–206, 2001.

[6] A. Manea, “NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology,” Cell and Tissue Research, vol. 342, no. 3, pp. 325–339, 2010.

[7] L. Xiao, Y. Liu, and N. Wang, “New paradigms in inflammatory signaling in vascular endothelial cells,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 306, no. 3, pp. H317–H325, 2014.

[8] S.-Y. Wei, Y. Chen, and X.-Y. Xu, “Progress on the pharmacological research of puerarin: a review,” Chinese Journal of Natural Medicines, vol. 12, no. 6, pp. 407–414, 2014.

[9] Y.-X. Zhou, H. Zhang, and C. Peng, “Puerarin: a review of pharmacological effects,” Phytotherapy Research, vol. 28, no. 7, pp. 961–975, 2014.

[10] F.-L. Hsu, I.-M. Liu, D.-H. Kuo, W.-C. Chen, H.-C. Su, and J.-T. Cheng, “Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats,” Journal of Natural Products, vol. 66, no. 6, pp. 788–792, 2003.
E. Kato and J. Kawabata, “Glucose uptake enhancing activity of puerarin and the role of C-glucoside suggested from activity of related compounds,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 15, pp. 4333–4336, 2010.

Y. Teng, H. Cui, M. Yang et al., “Protective effect of puerarin on diabetic retinopathy in rats,” Molecular Biology Reports, vol. 36, no. 5, pp. 1129–1133, 2009.

W. Zhang, C.-Q. Liu, P.-W. Wang et al., “Puerarin improves insulin resistance and modulates adipokine expression in rats fed a high-fat diet,” European Journal of Pharmacology, vol. 649, no. 1–3, pp. 398–402, 2010.

Z. Li, Z. Shangguan, Y. Liu et al., “Puerarin protects pancreatic β-cell survival via PI3K/Akt signaling pathway,” Journal of Molecular Endocrinology, vol. 53, no. 1, pp. 71–79, 2014.

W. Cheng, P. Wu, Y. Du et al., “Puerarin improves cardiac function through regulation of energy metabolism in Streptozotocin-Nicotinamide induced diabetic mice after myocardial infarction,” Biochemical and Biophysical Research Communications, vol. 463, no. 4, pp. 1108–1114, 2015.

S. She, W. Liu, T. Li, and Y. Hong, “Effects of puerarin in STZ-induced diabetic rats by oxidative stress and the TGF-β1/Smad2 pathway,” Food and Function, vol. 5, no. 5, pp. 944–950, 2014.

Y. Zhong, X. Zhang, X. Cai, K. Wang, Y. Chen, and Y. Deng, “Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats,” PloS ONE, vol. 9, no. 1, Article ID e85690, 2014.

F. Braga, A. Dolci, A. Mosca, and M. Panteghini, “Biological variability of glycated hemoglobin,” Clinica Chimica Acta, vol. 411, no. 21–22, pp. 1606–1610, 2010.

N. Li, “The influence of puerarin on glycated hemoglobin, MDA, and SOD in diabetic patients,” Guangxi Medical Journal, vol. 19, p. 3, 1997.

K. Wu, T. Liang, X. Duan, L. Xu, K. Zhang, and R. Li, “Anti-diabetic effects of puerarin, isolated from Pueraria lobata (Willd.), on streptozotocin-diabetogenic mice through promoting insulin expression and ameliorating metabolic function,” Food and Chemical Toxicology, vol. 60, pp. 341–347, 2013.

S.-F. Yang, W. Je Lee, E.-A. Kim et al., “Effects of N-adamantyl-4-methylthiazol-2-amine on hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats,” European Journal of Pharmacology, vol. 736, pp. 26–34, 2014.

N. Giribabu, K. E. Kumar, S. S. Rekha et al., “Chlorophytum borivilianum (Safed Musli) root extract prevents impairment in characteristics and elevation of oxidative stress in sperm of streptozotocin-induced adult male diabetic Wistar rats,” BMC Complementary and Alternative Medicine, vol. 14, article 291, 2014.

C. Szabo, “Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction,” British Journal of Pharmacology, vol. 156, no. 5, pp. 713–727, 2009.

K. Fujii, M. Soma, Y.-S. Huang, M. S. Manku, and D. F. Horrobin, “Increased release of prostaglandins from the mesenteric vascular bed of diabetic animals: the effects of glucose and insulin,” Prostaglandins, Leukotrienes and Medicine, vol. 24, no. 2-3, pp. 151–161, 1986.

E. Capobianco, A. Javerbaum, W. White, C. Pustovrh, D. Sinner, and E. T. Gonzalez, “Elevated levels of endothelin-1 and prostaglandin E2 and their effect on nitric oxide generation in placental tissue from neonatal streptozotocin-induced diabetic rats,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 68, no. 3, pp. 225–231, 2003.

W.-Y. Wu, H. Yan, X.-B. Wang et al., “Sodium tanshinone IIA silicate inhibits high glucose-induced vascular smooth muscle cell proliferation and migration through activation of AMP-activated protein kinase,” PLoS ONE, vol. 9, no. 4, Article ID e94957, 2014.

Q. Lu, D.-X. Xiang, H.-Y. Yuan, Y. Xiao, L.-Q. Yuan, and H.-B. Li, “Puerarin attenuates calcification of vascular smooth muscle cells,” American Journal of Chinese Medicine, vol. 42, no. 2, pp. 337–347, 2014.

L.-H. Zhu, L. Wang, D. Wang et al., “Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCβ2/Rac1-dependent signaling,” Free Radical Biology and Medicine, vol. 48, no. 4, pp. 471–482, 2010.

M. Zhu, J. Chen, H. Jiang, and C. Miao, “Propofol protects against high glucose-induced endothelial adhesion molecules expression in human umbilical vein endothelial cells,” Cardiovascular Diabetology, vol. 12, no. 1, article 13, 2013.

L. Li, T. Sawamura, and G. Renier, “Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte endothelial cell endothotheliolysis,” Diabetes, vol. 52, no. 7, pp. 1843–1850, 2003.

J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic complications,” Physiological Reviews, vol. 93, no. 1, pp. 137–188, 2013.

Y. Gorin and K. Block, “Nox as a target for diabetic complications,” Clinical Science, vol. 125, no. 8, pp. 361–382, 2013.

A. Schramm, P. Matusik, G. Osmenda, and T. J. Gузik, “Targeting NADPH oxidases in vascular pharmacology,” Vascular Pharmacology, vol. 56, no. 5-6, pp. 216–231, 2012.

J. Kim, K. M. Kim, C.-S. Kim et al., “Puerarin inhibits the retinal pericyte apoptosis induced by advanced glycation end products in vitro and in vivo by inhibiting NADPH oxidase-related oxidative stress,” Free Radical Biology and Medicine, vol. 53, no. 2, pp. 357–365, 2012.

M. Buelna-Chontal and C. Zazueta, “Redox activation of Nrf2 & NF-κB: a double end sword?” Cellular Signalling, vol. 25, no. 12, pp. 2548–2557, 2013.

L. Cominacini, A. Fratta Pasini, U. Garbin et al., “Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-κB through an increased production of intracellular reactive oxygen species,” The Journal of Biological Chemistry, vol. 275, no. 17, pp. 12633–12638, 2000.

Y. Sun and X. Chen, “Ox-LDL-induced LOX-1 expression in vascular smooth muscle cells: role of reactive oxygen species,” Fundamental and Clinical Pharmacology, vol. 25, no. 5, pp. 572–579, 2011.

R. B. Ning, J. Zhu, D. J. Chai et al., “RXR agonists inhibit high glucose-induced upregulation of inflammation by suppressing activation of the NADPH oxidase-nuclear factor-κB pathway in human endothelial cells,” Genetics and Molecular Research, vol. 12, no. 4, pp. 6692–6707, 2013.

G.-F. Wang, S.-Y. Wu, W. Xu et al., “Geniposide inhibits high glucose-induced cell adhesion through the NF-kappaB signaling pathway in human umbilical vein endothelial cells,” Acta Pharmacologica Sinica, vol. 31, no. 8, pp. 953–962, 2010.